These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27913493)

  • 1. Novel agents in follicular lymphoma: choosing the best target.
    Sehn LH
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):284-292. PubMed ID: 27913493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular lymphoma: The long and winding road leading to your cure?
    Gordon MJ; Smith MR; Nastoupil LJ
    Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of obinutuzumab in the management of follicular lymphoma.
    O'Nions J; Townsend W
    Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.
    Boughan KM; Caimi PF
    Curr Oncol Rep; 2019 May; 21(7):63. PubMed ID: 31119485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation of follicular lymphoma - Why does it happen and can it be prevented?
    Link BK
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):49-56. PubMed ID: 29452666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
    Fowler N
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):277-283. PubMed ID: 27913492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of microenvironment in follicular lymphoma.
    Nowakowski GS; Ansell SM
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):169-73. PubMed ID: 25696851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma.
    Pon JR; Marra MA
    Blood; 2016 Jan; 127(2):181-6. PubMed ID: 26447189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.
    Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S
    Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk follicular lymphoma: Treatment options.
    Kahl B
    Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory Agents in Follicular Lymphoma.
    Ysebaert L; Morschhauser F
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular lymphoma: evolving therapeutic strategies.
    Kahl BS; Yang DT
    Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.
    Cánovas A; Alonso JJ; Barreiro G; Aguirre C
    Tumori; 2010; 96(1):117-21. PubMed ID: 20437868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies for Follicular Lymphoma.
    Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
    Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents for relapsed and refractory follicular lymphoma.
    Cheah CY; Fowler NH
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):41-48. PubMed ID: 29452665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of genetic targets for guiding clinical management of follicular lymphoma.
    Alonso-Alonso R; Rodriguez M; Morillo D; Cordoba R; Piris MA
    Expert Rev Hematol; 2020 Dec; 13(12):1361-1372. PubMed ID: 33176509
    [No Abstract]   [Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of follicular lymphoma: current status.
    Tilly H; Zelenetz A
    Leuk Lymphoma; 2008; 49 Suppl 1():7-17. PubMed ID: 18821428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follicular lymphoma patients with a high FLIPI score and a high tumor burden: a risk stratification model.
    Andjelić B; Todorović-Balint M; Antić D; Bila J; Djurašinović V; Mihaljević B
    Vojnosanit Pregl; 2015 Jan; 72(1):26-32. PubMed ID: 26043587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.